Pulse Biosciences (NASDAQ:PLSE) Trading Down 2.2% - Time to Sell?

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares were down 2.2% during mid-day trading on Thursday . The stock traded as low as $17.75 and last traded at $17.92. Approximately 39,761 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 199,232 shares. The stock had previously closed at $18.33.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research note on Tuesday.

Pulse Biosciences Stock Performance

The company's 50 day simple moving average is $17.99 and its 200-day simple moving average is $16.71.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the prior year, the firm posted ($0.19) earnings per share.

Insider Activity

In other news, CEO Burke Thomas Barrett sold 50,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the transaction, the chief executive officer now directly owns 63,172 shares of the company's stock, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert W. Duggan acquired 56,054 shares of Pulse Biosciences stock in a transaction on Wednesday, December 11th. The shares were purchased at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the acquisition, the director now directly owns 42,228,057 shares in the company, valued at $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company's stock.

Institutional Trading of Pulse Biosciences

Hedge funds have recently bought and sold shares of the stock. Quest Partners LLC acquired a new position in Pulse Biosciences during the 2nd quarter valued at about $91,000. Rhumbline Advisers increased its holdings in shares of Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock valued at $288,000 after acquiring an additional 1,608 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of Pulse Biosciences in the 3rd quarter valued at approximately $378,000. Creative Planning boosted its stake in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock worth $384,000 after purchasing an additional 11,667 shares in the last quarter. Finally, Barclays PLC grew its position in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock worth $530,000 after purchasing an additional 23,738 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.